Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model

Cybin, a biotech company focused on progressing psychedelic therapeutics, has announced that the FDA has given them authorization for Phase 2 clinical trials evaluating psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress.

Category Press Release
Country Canada

Companies Featured

Cybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.